The pharmaceutical sector is really unpredictable this time. Pfizer moved sideways with a +0.08% gain, and the market doesn't believe in anything. But high-volatility biotech small caps like Merck and CRISPR took turns surging, with Abivax skyrocketing 20% instantly. I suddenly felt like an old bagholder who missed the stock's momentum.

There are so many biotech stories recently. Just one piece of news from Eli Lilly got everyone excited.

If you bet right, you'd be gloating; if you missed out, you'd be left with nothing but sour grapes. But you have to admit, the biopharma sector is like a blind box—you're afraid of missing out but also afraid of landmines. The only option is to hold with a zen mindset, waiting for your stock to pop someday.